Logo Studenta
17 pág.

Vista previa | Página 5 de 6

N Am. 2010; 19(4):819-27. 
9. Schmoll HJ, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A 
personalized approach to clinical decision making. Ann Oncol. 2012; 23(10): 2479-516. 
10. Gray R, et al. Adyuvant chemotherapy versus observation in patients with colorectal cancer: a randomised 
study. Lancet. 2007; 370(9604): 2020-9. 
11. Glimelius B, et al. Nordic Gastrointestinal Tumour Adyuvant Therapy group. Adyuvant chemotherapy in 
colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Adyuvant therapy 
group. Acta Oncol. 2005; 44(8): 904-12. 
12. Hartung G, et al. Adyuvant therapy with edrecolomab versus observation in stage II colon cancer. Onkologie. 
2005 Jun; 28(6-7):347-50. 
13. Schippinger W, et al. Austrian Breast and Colorectal Cancer Study Group. A prospective randomised phase 
III trial of adyuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon 
cancer. Br J Cancer 2007; 97(8): 1021-7. 
14. Watanabe M, et al. Randomised trial of the efficacy of adyuvant chemotherapy for colon cancer with 
combination therapy incorporating the oral pyrimidine 1-hexylcarbamoyl 1.5.fluorouracil. Langenbecks 
Arch Surg. 2006; 391(4): 330-7. 
15. IMPACT B2 investigators. Efficacy of adyuvant fluorouracil and folinic acid in B2 colon cancer. International 
Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol. 1999; 
17(5): 1356-73. 
16. Gill S, et al. Pooled analysis on fluorouracil-based adyuvant therapy for stage II and III colon cancer: who 
benefits and how much? J Clin Oncol. 2004; 22(10): 1797-806. 
17. Wilkinson NW, et al. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and 
leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A 
baseline from which to compare modern adyuvant trials. Ann Surg Oncol. 2010;17(4): 959-66. 
18. Wu X, et al. Postoperative adjuvant chemotherapy for stage II colorectal cancer: a systematic review of 12 
randomized control trials. J Gastrointest Surg. 2012; 16(3): 646-55. 
19. André T, et al. Improved overall survival with oxaliplatin, fluorouracil and leucovorin as adyuvant treatment in 
stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009; 27: 3109-16. 
20. Tournigand C, et al. Adyuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients 
(between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International 
Study of Oxaliplatin, Fluorouracil and Leucovorin in the Adyuvant Treatment of Colon Cancer trial. J Clin 
Oncol. 2012; 30(27): 3353-60. 
21. Yothers G, et al. Oxaliplatin as adyuvant therapy for colon cancer: updated results of NSABP C-07 trial, 
including survival and subset analyses. J Clin Oncol. 2011; 29(28): 3768-74. 
22. Schrag D, et al. Adyuvant chemotherapy use of Medicare beneficiaries with stage II colon cancer. J Clin 
Oncol. 2002; 20: 3999-4005. 
23. Buyse M, et al. Should Dukes`B patients recieve adyuvant therapy? A Statistical perspective. Semin Oncol. 
2001; 28(1 Suppl 1): 20-4. 
24. Gryfe R, et al. Tumor microsatellite-instability and clinical outcome in young patients with colorectal cancer. 
N Engl J Med. 2000;342(2): 69-77. 
25. Ribic CM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based 
adjuvant chemotherapy for colon cancer. N Engl J Med. 2003; 349(3): 247-57. 
26. Compton CC, at al. Prognostic factors in colorectal cancer. College of American	
  Pathologists Consensus 
Statement 1999. Arch Pathol Lab Med. 2000; 124(7): 979-94. 
27. Quah HM, et al. Identifications of patients with high risk stage II colon cancer for adjuvant therapy. 2008; 
28. Gertler, R, et al. Defining a high risk subgroup with colon cancer stages I and II for posible adjuvant therapy. 
2009; 45(17):2992-9. 
29. Benson AB 3rd, et al. American Society of Clinical Oncology recommendations on adyuvant 
chemotherapyfor stage II colon cancer. J Clin Oncol. 2004; 22(16):3408-19. 
30. Hendriks YM, et al. Diagnostic approach and management of Lynch síndrome (hereditary nonpolyposis 
colorectal carcinoma: a guide for clinicians. CA Cancer J Clin. 2006; 56: 213-25. 
31. Boland CR, et al. The International Workshop on Microsatellite Instability and RER phenotypes in cancer 
detection and familial predisposition. Cancer Res. 1998; 58:5248-57. 
32. Benatti P, et al. Microsatellite imstability and colorectal cancer prognosis. Clin Cancer Res. 2005; 11(23): 
34. World Health Organization. Obesity ans overweight. Fac sheet Nº311. Consultado en 
35. Barquera S, et al. Prevalencia de obesidad en adultos mexicanos, 2000-2012. Salud Pública Méx. 2013; 
55(Supl 2): S151-60. 
36. Calle EE, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. 
adults. N Engl J Med. 2003; 348(17): 1625-38. 
37. De Pergola G, et al. Obesity as a major risk factor for cancer. J Obes. 2013; 291546. Epub 19 Ago 2013. 
38. Bhaskaran K, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 
5.24 million UK adults. Lancet. 2014; 384(9945): 755-65. 
39. Harriss DJ, et al. Lifestyle factors and cancer risk (1): systematic review and meta-analysis of associations 
with body mass index. Colorectal Dis. 2009; 11(6): 547-63. 
40. Bardou M , et al. Obesity and colorectal cancer. Gut 2013; 62(6): 933-47. 
41. Guffey, CR, et al. Linking obesity to colorectal cancer: recent insights info plausible biological mechanisms. 
Curr Opin Clin Nutr Metab care. 2013; 16(5): 595-600. 
42. Gribovskaja-Rupp I, et al. Obesity and colorectal cancer. Clin Colon Rectal Surg. 2011; 24(4): 229-43. 
43. Yamamoto N, et al. Impact of body mass index and visceral adiposity on outcomes with colorectal cancer. 
Asia Pac J clin Oncol. 2012; 8(4): 337-45. 
44. Meyerhardt JA, et al. Impact of body mass index and weight change after treatment on cancer recurrence 
and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. 
J Clin Oncol. 2008; 26(25): 4109-15. 
45. Meyerhardt JA, et al. Influence of body mass index on outcomes and treatment-related tocicity in patients 
with colon carcinoma. Cancer. 2003; 98(3): 484-95. 
46. Dignam JJ, et al. Body mass index and outcomes in patients who recieve adjuvant chemotherapy for colon 
cancer. J Natl Cancer Inst. 2006; 98(22): 1647-54. 
47. Sinicrope FA, et al. Obesity is an independent prognostic variable in colon cancer survivors. Clin Can Res. 
2010; 16(6): 1884-93. 
48. Sinicrope FA, et al. Body mass index at diagnosis and survival among colon cancer patients enrolled in 
clinical trials of adjuvant chemotherapy. Cancer. 2013; 119(8): 1528-36. 
49. Campbell PT, et al. Impact of body mass index on survival after colorectal cancer diagnosis: the Cancer 
Prevention Study –II Nutrition Cohort. J Clin Oncol. 2012; 30(1): 42-52. 
50. Haydon AMM, et al. Effect of physical activity and body size on survival after diagnosis with colorectal 
cancer. Gut. 2006; 55(1): 62-7 
51. Prizment AE, et al. Survival of women with colon cancer in relation to precancer anthopometric 
characteristics: the Iowa Womens’s Health Study. Cancer Epidemiol Biomarkers Prev. 2010; 19(9): 
52. Fedirko V, et al. Pre-diagnostic anthropometry and survival after colorectal cancer diagnoisis in Western 
european populations. Int J Cancer. 2014; 135(8): 1949-60. 
53. Makino T, et al. The impact of obesity on perioperative outcomes after laparoscopic colorectal resection. 
Ann Surg. 2012; 255(2): 228-36. 
54. Zhou, Y, et al. Outcome of laparoscopic colorectal surgery in obese and nonobese patients: a meta-analysis. 
Surg Endosc. 2012; 26(3):783-9.